Xenon Pharmaceuticals has presented compelling data from the Phase 3 X-TOLE2 study at the American Academy of Neurology (AAN) Annual Meeting, showcasing the efficacy of azetukalner (AZK) in treating focal onset seizures (FOS). The study revealed a 53.2% reduction in monthly seizure frequency for the 25 mg AZK group compared to a mere 10.4% for placebo, with a notable increase in the rate of 100% seizure reduction over time during the 12-week double-blind period. Long-term results from the ongoing X-TOLE open-label extension (OLE) study indicate that nearly 40% of participants achieved at least 12 months of seizure freedom, while 25% achieved 24 months, underscoring AZK’s potential as a transformative treatment for epilepsy.

The significance of these findings lies in AZK’s unique mechanism as a KV7 potassium channel opener, which may facilitate improved neuronal hyperpolarization and reduce excessive firing associated with seizures. The study population was notably treatment-resistant, with a median baseline seizure frequency of 13 seizures per month and a history of multiple failed treatments. The sustained efficacy observed, particularly the increasing rates of seizure freedom over time, suggests that AZK could address a critical gap in the management of refractory epilepsy, offering a new therapeutic avenue for patients who have exhausted other options.

The implications for the field are substantial. AZK’s profile as a no-titration, once-daily medication could significantly streamline treatment regimens, alleviating the burden of complex medication schedules for both patients and clinicians. This ease of use may enhance patient adherence and confidence in treatment, shifting the paradigm toward more accessible and effective management of epilepsy. As Xenon prepares to submit a New Drug Application (NDA) to the FDA, the potential for AZK to become a first-line option in epilepsy management is on the horizon, promising a much-needed innovation in anti-seizure medications.

Source: globenewswire.com